The Wnt signaling pathway in cancer

Critical Reviews in Oncology/Hematology

Volumn 99, Issue , 2016, Pages 141-149

  Duchartre, Yann ^a   Kim, Yong Mi ^a   Kahn, Michael ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer Stem Cells; Microenvironment; Wnt signaling

Indexed keywords

PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN INHIBITOR;

CANCER RESEARCH; CANCER STEM CELL; CARCINOGENESIS; CELL FUNCTION; DISEASE ASSOCIATION; DRUG SAFETY; EMBRYO DEVELOPMENT; GENE EXPRESSION REGULATION; GENE TARGETING; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; STEM CELL NICHE; WNT SIGNALING PATHWAY;

EID: 84959527865     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.12.005     Document Type: Review

References (146)

1. Abrahamsson A.E., et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3925-3929.
2. Ahmed M.A., et al. CD24 is upregulated in inflammatory bowel disease and stimulates cell motility and colony formation. Inflamm. Bowel. Dis. 2010, 16:795-803.
3. Ahn J.Y., Park G., Shim J.S., Lee J.W., Oh I.H. Intramarrow injection of beta-catenin-activated, but not naive mesenchymal stromal cells stimulates self-renewal of hematopoietic stem cells in bone marrow. Exp. Mol. Med. 42 2010, 12:2-131.
4. Al-Hajj M., Wicha M.S., ito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A 2003, 100:3983-3988.
5. Alonso L., Fuchs E. Stem cells in the skin: waste not, Wnt not. Genes Dev. 2003, 17:1189-1200.
6. Austin T.W., Solar G.P., Ziegler F.C., Liem L., Matthews W. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood 1997, 89:3624-3635.
7. Baker N.E. Molecular cloning of sequences from wingless, a segment polarity gene in Drosophila: the spatial distribution of a transcript in embryos. EMBO J. 1987, 6:1765-1773.
8. Baron J.A., et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 2003, 348:891-899.
9. Boon E.M., et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br. J. Cancer 2004, 90:224-229.
10. Boulais P.E., Frenette P.S. Making sense of hematopoietic stem cell niches. Blood 2015, 125:2621-2629.
11. Bowers M., et al. Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development. Blood 2015, 125:2678-2688.
12. Brabletz T., et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005, 179:56-65.
13. Brembeck F.H., Rosario M., Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr. Opin. Genet. Dev. 2006, 16:51-59.
14. Brudvik K.W., Paulsen J.E., Aandahl E.M., Roald B., Tasken K. Protein kinase A antagonist inhibits beta-catenin nuclear translocation: c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice. Mol. Cancer 2011, 10:149.
15. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310:1504-1510.
16. Chen J., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
17. Choi M.Y., et al. Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1. Clin. Lymphoma Myeloma. Leuk. 2015, 15(Suppl):S167-S169.
18. Chua H.H., et al. RBMY, a novel inhibitor of glycogen synthase kinase 3beta, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma. Hepatology 2015.
19. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17:313-319.
20. Cobas M., et al. Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J. Exp. Med. 2004, 199:221-229.
21. Conacci-Sorrell M., et al. Autoregulation of E-cadherin expression bycadherin-cadherin interactions: the roles of beta-catenin signaling, slug, and MA PK. J. Cell Biol. 2003, 163:847-857.
22. Dandekar S., et al. Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 2014, 167:87-99.
23. De T.F., et al. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 2006, 25:3113-3122.
24. De M.C., et al. Dual cyclooxygenase and carbonic anhydrase inhibition by nonsteroidal anti-inflammatory drugs for the treatment of cancer. Curr. Med. Chem. 2015, 22:2812-2818.
25. DiMeo T.A., et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009, 69:5364-5373.
26. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488:527-530.
27. DuBois R.N., Giardiello F.M., Smalley W.E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am. 1996, 25:773-791.
28. El-Khoueiry A.B., Ning Y., Yang D., Cole S., Kahn M., Zoghbi M., Berg J., Fujimori M., Inada T., Kouji H., Lenz H.-J. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J. Clin. Oncol. 2013, 31. (suppl; abstract 2501).
29. Emami K.H., et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:12682-12687.
30. Espinoza I., Miele L. Deadly crosstalk: notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett. 2013, 341:41-45.
31. Fang D., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 65:9328-9337.
32. Fleming H.E., et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2008, 2:274-283.
33. Florian M.C., et al. A canonical to non-canonical Wnt signalling switch in haematopoietic stem-cell ageing. Nature 2013, 503:392-396.
34. Fujii N., et al. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res. 2007, 67:573-579.
35. Gang E.J., et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2014, 33:2169-2178.
36. Giambra V., et al. Leukemia stem cells in T-ALL require active Hif1alpha and Wnt signaling. Blood 2015, 125:3917-3927.
37. Grandy D., et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. 2009, 284:16256-16263.
38. Gregorieff A., Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 2005, 19:877-890.
39. Grosch S., Tegeder I., Niederberger E., Brautigam L., Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001, 15:2742-2744.
40. Gurney A., et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci. U. S. A 2012, 109:11717-11722.
41. Han J., et al. Small interfering RNA-mediated downregulation of beta-catenin inhibits invasion and migration of colon cancer cells in vitro. Med. Sci. Monit. 2012, 18:BR273-BR280.
42. Heidel F.H., et al. Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 2012, 10:2-424.
43. Heuberger J., Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb. Perspect. Biol. 2010, 2:a002915.
44. Huang S.M., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
45. Huels D.J., et al. E-cadherin can limit the transforming properties of activating beta-catenin mutations. EMBO J. 2015, 34:1-2333.
46. Hussenet T., Dembele D., Martinet N., Vignaud J.M., du M.S. An adult tissue-specific stem cell molecular phenotype is activated in epithelial cancer stem cells and correlated to patient outcome. Cell Cycle 2010, 9:321-327.
47. Jamieson C.H., Weissman I.L., Passegue E. Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell 2004, 6:1-533.
48. Jamieson C.H., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 2004, 351:657-667.
49. Jansen S.R., et al. Prostaglandin E2 promotes MYCN non-amplified neuroblastoma cell survival via beta-catenin stabilization. J. Cell Mol. Med. 2015, 19:210-226.
50. Jeannet G., et al. Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood 2008, 111:142-149.
51. Kabiri Z., et al. Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells. Blood 2015, 126:1086-1094.
52. Kadowaki T., Wilder E., Klingensmith J., Zachary K., Perrimon N. The segment polarity gene porcupine encodes a putative multitransmembrane protein involved in Wingless processing. Genes Dev. 1996, 10:3116-3128.
53. Kahn M. Can we safely target the WNT pathway?. Nat. Rev. Drug Discov. 2014, 13:513-532.
54. Kim J.A., et al. Identification of a stroma-mediated Wnt/beta-catenin signal promoting self-renewal of hematopoietic stem cells in the stem cell niche. Stem Cell 2009, 27:1318-1329.
55. Kimelman D., Xu W. Beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 2006, 25:7482-7491.
56. Kirstetter P., Anderson K., Porse B.T., Jacobsen S.E., Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat. Immunol. 2006, 7:1048-1056.
57. Klaus A., Birchmeier W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 2008, 8:387-398.
58. Klonisch T., et al. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol. Med. 2008, 14:450-460.
59. Kode A., et al. FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice. Leukemia 2015, 161. 10.1038/leu.2015.
60. Krivtsov A.V., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
61. Ksiazkiewicz M., Markiewicz A., Zaczek A.J. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 2012, 79:195-208.
62. Kulak O., et al. Disruption of Wnt/beta-catenin signaling and telomeric shortening are inextricable consequences of tankyrase inhibition in human cells. Mol. Cell Biol. 2015, 35:2425-2435.
63. L'Episcopo F., et al. Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/beta-catenin signaling pathways: functional consequences for neuroprotection and repair. J. Neurosci. 2012, 32:2062-2085.
64. Lai S.L., Chien A.J., Moon R.T. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res. 2009, 19:532-545.
65. Lane S.W., et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood 2011, 118:2849-2856.
66. Lapidot T., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
67. Le P.N., McDermott J.D., Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol. Ther. 2015, 146:1-11.
68. Li C., et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
69. Li L., et al. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell 2014, 15:431-446.
70. Liu J., Sato C., Cerletti M., Wagers A. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr. Top. Dev. Biol. 2010, 92:7-409.
71. Liu C.C., et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease. Neuron 2014, 84:3-77.
72. Luis T.C., Ichii M., Brugman M.H., Kincade P., Staal F.J. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia 2012, 26:414-421.
73. Ma S., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132:2542-2556.
74. Madan B., et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene 2015.
75. Maier T.J., Janssen A., Schmidt R., Geisslinger G., Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J. 2005, 19:3-1355.
76. Malhotra S., Kincade P.W. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell 2009, 4:27-36.
77. Malhotra S., Kincade P.W. Canonical Wnt pathway signaling suppresses VCAM-1 expression by marrow stromal and hematopoietic cells. Exp. Hematol. 2009, 37:19-30.
78. Manabe A., Coustan-Smith E., Behm F.G., Raimondi S.C., Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992, 79:2370-2377.
79. McCarthy N. Cancer stem cells: tracing clones. Nat. Rev. Cancer 2012, 12:579.
80. McMahon A.P., Moon R.T. Ectopic expression of the proto-oncogene int-1 in Xenopus embryos leads to duplication of the embryonic axis. Cell 1989, 58:1075-1084.
81. McMillan M., Kahn M. Investigating Wnt signaling: a chemogenomic safari. Drug Discov. Today 2005, 10:1467-1474.
82. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9:665-674.
83. Merchant A.A., Matsui W. Targeting hedgehog-a cancer stem cell pathway. Clin. Cancer Res. 2010, 16:3130-3140.
84. Miki T., Yasuda S.Y., Kahn M. Wnt/beta-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev. 2011, 7:836-846.
85. Mlodzik M. Planar cell polarization: do the same mechanisms regulate Drosophila tissue polarity and vertebrate gastrulation?. Trends Genet. 2002, 18:564-571.
86. Monga S.P. Beta-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology 2015, 148:1294-1310.
87. Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 2004, 5:691-701.
88. Moon R.T. Wnt/beta-catenin pathway. Sci. STKE 2005, cm1.
89. Moreno-Bueno G., Portillo F., Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008, 27:6958-6969.
90. Morrison S.J., Scadden D.T. The bone marrow niche for haematopoietic stem cells. Nature 2014, 505:327-334.
91. Mosimann C., Hausmann G., Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat. Rev. Mol. Cell Biol. 2009, 10:276-286.
92. Nakamura T., et al. Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level. Genes Cells 1998, 3:395-403.
93. Nath N., Kashfi K., Chen J., Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12584-12589.
94. Niehrs C. The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 2012, 13:767-779.
95. Nusse R., Varmus H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31:99-109.
96. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
97. O'Brien C.A., Kreso A., Jamieson C.H. Cancer stem cells and self-renewal. Clin. cancer Res. 2010, 16:3113-3120.
98. Palmer H.G., et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 2001, 154:369-387.
99. Phillips R.K., et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002, 50:857-860.
100. Pinto D., Clevers H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp. Cell Res. 2005, 306:357-363.
101. Radich J.P., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2794-2799.
102. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
103. Riether C., et al. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci. Transl. Med. 2015, 7:298ra119.
104. Rios-Esteves J., Resh M.D. Stearoyl CoA desaturase is required to produce active, lipid-modified Wnt proteins. Cell Rep. 2013, 4:1072-1081.
105. Roman-Gomez J., et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 2007, 109:3462-3469.
106. Sadarangani A., et al. GLI2 inhibition abrogates human leukemia stem cell dormancy. J. Transl. Med. 2015, 13:98.
107. Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 2003, 348:883-890.
108. Sawa H. Control of cell polarity and asymmetric division in C elegans. Curr. Top. Dev. Biol. 2012, 101:55-76.
109. Schambony A., Wedlich D. Wnt-5A/Ror2 regulate expression of XPAPC through an alternative noncanonical signaling pathway. Dev. Cell 2007, 12:779-792.
110. 5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735.
111. Schmitt M., Metzger M., Gradl D., Davidson G., Orian-Rousseau V. CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death. Differ. 2015, 22:677-689.
112. Schurch C., Riether C., Matter M.S., Tzankov A., Ochsenbein A.F. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J. Clin. Invest. 2012, 122:624-638.
113. Shan J., Shi D.L., Wang J., Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005, 44:15495-15503.
114. Shulewitz M., et al. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. Oncogene 2006, 25:4361-4369.
115. Singh S.K., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
116. Smalley W.E., DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 1997, 39:1-20.
117. Smith, et al. J. Clin. Oncol. 2013, 31. (suppl; abstr 2540).
118. Steinbach G., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342:1946-1952.
119. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin. Cancer Res. 2010, 16:3153-3162.
120. Tegeder I., et al. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J. 2001, 15:2-4.
121. Teo J.L., Kahn M. The Wnt signaling pathway in cellular proliferation and differentiation: a tale of two coactivators. Adv. Drug Deliv. Rev. 2010, 62:1149-1155.
122. Thrasivoulou C., Millar M., Ahmed A. Activation of intracellular calcium by multiple Wnt ligands and translocation of beta-catenin into the nucleus: a convergent model of Wnt/Ca2+ and Wnt/beta-catenin pathways. J. Biol. Chem. 2013, 288:35651-35659.
123. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94:252-266.
124. Valencia A., et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia 2009, 23:1658-1666.
125. Van Den Berg D.J., Sharma A.K., Bruno E., Hoffman R. Role of members of the Wnt gene family in human hematopoiesis. Blood 1998, 92:3189-3202.
126. van A.R., Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009, 136:3205-3214.
127. Veeman M.T., Axelrod J.D., Moon R.T. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev. Cell 2003, 5:367-377.
128. Vermeulen L., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476.
129. Visvader J.E., Lindeman G.J. Stem cells and cancer-the promise and puzzles. Mol. Oncol. 2010, 4:369-372.
130. Voronkov A., Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Curr. Pharm. Des. 2013, 19:634-664.
131. Wang L.D., Wagers A.J. Dynamic niches in the origination and differentiation of haematopoietic stem cells. Nat. Rev. Mol. Cell Biol. 2011, 12:643-655.
132. Wang Y., et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
133. Welters H.J., Kulkarni R.N. Wnt signaling: relevance to beta-cell biology and diabetes. Trends Endocrinol. Metab. 2008, 19:349-355.
134. Wicha M.S. Migratory gene expression signature predicts poor patient outcome: are cancer stem cells to blame?. Breast Cancer Res. 2012, 14:114.
135. Wielenga V.J., et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 1999, 154:515-523.
136. Willert K., Jones K.A. Wnt signaling: is the party in the nucleus?. Genes Dev. 2006, 20:1394-1404.
137. Williams J.L., et al. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res. 2001, 61:3285-3289.
138. Williams J.L., et al. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem. Biophys. Res. Commun. 2004, 313:784-788.
139. Xiao J.H., et al. Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J. Biol. Chem. 2003, 278:29954-29962.
140. Yamada T., et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res. 2000, 60:4761-4766.
141. Yamamoto S., et al. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev. Cell 2008, 15:23-36.
142. Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 2002, 531:278-284.
143. Yang K., et al. Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. Carcinogenesis 2003, 24:605-611.
144. Zhang Z., Lai G.H., Sirica A.E. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004, 39:1028-1037.
145. Zhang B., et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 2013, 121:1824-1838.
146. Zhao Y., Masiello D., McMillian M., Nguyen C., Wu Y., Melendez E., Smbatyan G., Kida A., He Y., Teo J.L., Kahn M. Oncogene 2015, (December):14. [Epub ahead of print] PMID:26657156. 10.1038/onc.2015.438.